PDF(Pubmed)
Abstract：
UNASSIGNED: PTTG1 has been reported to be linked with the prognosis and progression of various cancers, including kidney renal clear cell carcinoma (KIRC). In this article, we mainly investigated the associations between prognosis, immunity, and PTTG1 in KIRC patients.
UNASSIGNED: We downloaded transcriptome data from the TCGA-KIRC database. PCR and immunohistochemistry were used, respectively, to validate the expression of PTTG1 in KIRC at the cell line and the protein levels. Survival analyses as well as univariate or multivariate Cox hazard regression analyses were used to prove whether PTTG1 alone could affect the prognosis of KIRC. The most important point was to study the relationship between PTTG1 and immunity.
UNASSIGNED: The results of the paper revealed that the expression levels of PTTG1 were elevated in KIRC compared with para-cancerous normal tissues, validated by PCR and immunohistochemistry at the cell line and the protein levels (P < 0.05). High PTTG1 expression was related to shorter overall survival (OS) in patients with KIRC (P < 0.05). Through univariate or multivariate regression analysis, PTTG1 was confirmed to be an independent prognostic factor for OS of KIRC (P < 0.05), and its related seven pathways were obtained through gene set enrichment analysis (GSEA; P < 0.05). Moreover, tumor mutational burden (TMB) and immunity were found to be significantly connected with PTTG1 in KIRC (P < 0.05). Correlations between PTTG1 and immunotherapy responses implied that the low-PTTG1 group was more sensitive to immunotherapy (P < 0.05).
UNASSIGNED: PTTG1 was closely associated with TMB or immunity, and it had a superior ability to forecast the prognosis of KIRC patients.
UNASSIGNED: We downloaded transcriptome data from the TCGA-KIRC database. PCR and immunohistochemistry were used, respectively, to validate the expression of PTTG1 in KIRC at the cell line and the protein levels. Survival analyses as well as univariate or multivariate Cox hazard regression analyses were used to prove whether PTTG1 alone could affect the prognosis of KIRC. The most important point was to study the relationship between PTTG1 and immunity.
UNASSIGNED: The results of the paper revealed that the expression levels of PTTG1 were elevated in KIRC compared with para-cancerous normal tissues, validated by PCR and immunohistochemistry at the cell line and the protein levels (P < 0.05). High PTTG1 expression was related to shorter overall survival (OS) in patients with KIRC (P < 0.05). Through univariate or multivariate regression analysis, PTTG1 was confirmed to be an independent prognostic factor for OS of KIRC (P < 0.05), and its related seven pathways were obtained through gene set enrichment analysis (GSEA; P < 0.05). Moreover, tumor mutational burden (TMB) and immunity were found to be significantly connected with PTTG1 in KIRC (P < 0.05). Correlations between PTTG1 and immunotherapy responses implied that the low-PTTG1 group was more sensitive to immunotherapy (P < 0.05).
UNASSIGNED: PTTG1 was closely associated with TMB or immunity, and it had a superior ability to forecast the prognosis of KIRC patients.
摘要：
未经证实：据报道，PTTG1与各种癌症的预后和进展有关，包括肾透明细胞癌（KIRC）。在这篇文章中,我们主要研究预后之间的关联，豁免权,KIRC患者的PTTG1。
UNASSIGNED：我们从TCGA-KIRC数据库下载了转录组数据。使用PCR和免疫组织化学，分别,验证PTTG1在KIRC细胞系和蛋白水平的表达。生存分析以及单变量或多变量Cox风险回归分析用于证明PTTG1单独是否会影响KIRC的预后。最重要的是研讨PTTG1与免疫的关系。
UNASSIGNED：论文的结果表明，与癌旁正常组织相比，KIRC中PTTG1的表达水平升高，通过PCR和免疫组织化学在细胞系和蛋白质水平上验证（P<0.05）。PTTG1高表达与KIRC患者总生存期(OS)缩短有关(P<0.05)。通过单变量或多元回归分析，PTTG1被证实是KIRCOS的独立预后因素(P<0.05)。并通过基因集富集分析(GSEA;P<0.05)获得了相关的7条通路。此外，在KIRC中发现肿瘤突变负荷（TMB）和免疫与PTTG1显着相关（P<0.05）。PTTG1与免疫治疗反应的相关性提示低PTTG1组对免疫治疗更敏感(P<0.05)。
未经证实：PTTG1与TMB或免疫力密切相关，对KIRC患者的预后有较好的预测能力。
UNASSIGNED：我们从TCGA-KIRC数据库下载了转录组数据。
UNASSIGNED：论文的结果表明，与癌旁正常组织相比，KIRC中PTTG1的表达水平升高，
未经证实：PTTG1与TMB或免疫力密切相关，
